abstract |
The use of fibroblast growth factor Fgf7 and of the corresponding receptor Fgfr2b as biomarker candidates for the progesterone receptor antagonist 11 β-(4-acetylphenyl)- 17β-hydroxy-17α-(1,1,2,2,2-pentafIuoroethyl)estra-4,9-dien-3-one, also known under the designations ZK230211 or ZK-PRA, of the Formula (I) and for antiestrogens is described. |